EMERGING LEADER IN STEM CELL THERAPY: HUMAN UMBILICAL CORD MESENCHYMAL STEM CELLS-FUTURE THERAPEUTIC TRENDS

Author:

Radhakrishnan Pradeep Kumar1,Ambat Roshini2,Vikraman Sushamma3,Nagasree N Geetha4,Hariharan Hariharan5,Swamy Victor Sitarama5,Sairama Varma Jutukonda6,Mohanty Sujatha7,Padmaja Jyothi8,Prakash Hema9,Bisoi A K10,Venugopal P11

Affiliation:

1. MS, Mch CTVS, Postdoctoral fellow ECMO, Postdoctoral Fellow CTVS, FACC, FIACS, CPDH,Global MBA, Chief Division of Cardiothoracic and Vascular Surgery- GIMSR Gitam University

2. MD DGO Sr Consultant KIMS

3. MD DGO, HOD Obs and Gynaecology KIMS

4. Sr Consultant MD DGO Care Hospitals Gachibowli

5. Student MBBS IIIrd year GIMSR Gitam University

6. IIIrd Yr MBBS Student GIMSR Gitam University

7. Head of Stem Cell Research MD AIIMS

8. MD Microbiology Principal GIMSR Gitam University

9. MD Microbiology, GIMSR Gitam University

10. Mch CTVS AIIMS

11. MS MCh CTVS, ExDirector and Advisor AIIMS New Delhi

Abstract

Mesenchymal stem cells (MSCs) are multipotent adult stem cells widely distributed in the bone marrow, umbilical cord, fat, and other tissues and have high proliferation, multi-differentiation, and immunoregulatory abilities. They can inhibit the proliferation of immune cells and the secretion of inammatory factors [26]. Compared with MSCs from other sources, human umbilical cord MSCs (hUCMSCs) have many advantages, such as a wide source, easy access to materials, strong proliferation ability, low immunogenicity, and great differentiation potential. They are most likely to become pluripotent stem cells with clinical application prospects. Wharton's jelly mesenchymal stem cells – WJMSC- provide three classic advantages – ease of collection with no legal or ethical issues, high differentiating potential and low immunogenicity. Shorter doubling time (21) and an extensive ex vivo expansion capacity provides yet another privileged status to these cells compared with embryonic stem cells. Therapeutic potential of these cells lie in their immuno-modulatory properties involving both innate and adaptive immunity. Graft vs Host disease (GvHD), Post transplant scenarios and autoimmune disorders could witness a revolution in treatment approach with greater understanding of the mechanism action of these cells. Regenerative medicine should get an immense benet from proper understanding and utilization of these cells.

Publisher

World Wide Journals

Reference29 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3